Almac Clinical Technologies Appoints Abi Pesun as Vice President of UK Operations

March 1, 2021

Craigavon, UK, 01 March 2021 – Almac Clinical Technologies, a member of the Almac Group, today announced the appointment of Abi Pesun to the position of Vice President of UK Operations.

In her role as VP, Abi will oversee the organisation’s United Kingdom Operations and staff, provide strategic direction for regional projects, and serve as executive sponsor for key accounts. She will also continue to oversee the operational team supporting Almac ONE – a unified clinical trial solution that harnesses over three decades of experience delivering Clinical Supplies services and Interactive Response Technology to redefine the Clinical Supply Chain experience, creating a responsive end-to-end process that enhances visibility and accuracy throughout the lifecycle of a clinical study.

Prior to her role as Vice President, Abi most recently served as Director of Clinical Project Services. She has been a key member of Clinical Technologies for 20 years, and notably played a pivotal role in the incorporation and expansion of Almac Clinical Technologies into Almac Group’s Headquarters site in Craigavon, Northern Ireland. 

Valarie Higgins, President and Managing Director of Almac Clinical Technologies, commented on Abi’s appointment: “We are pleased to congratulate Abi on her well-deserved promotion to our executive management team at Almac Clinical Technologies. She has made remarkable contributions to our clients and our organisation as she has progressed from Group Leader to Manager and then Director, most notably as a driving force behind our innovative unified clinical trial solution, Almac ONE, and for her leadership role in expanding our Craigavon office into the multi-site facility it is today. We look forward to seeing her unquestionable success in the future.”


About Almac Group

A unique culture delivering exceptional solutions

The Almac Group is an established contract development and manufacturing organisation providing an extensive range of integrated services across the drug development lifecycle to the pharmaceutical and biotech sectors globally.

Its innovative services range from R&D, biomarker discovery development and commercialisation, API manufacture, analytical services, formulation development, clinical trial supply, IRT (IVRS/IWRS) through to commercial-scale manufacture.

The international company is a privately owned organisation which has grown organically over the past five decades now employing over 5,600 highly skilled personnel across 18 facilities including Europe, the US and Asia.

To keep up to date with latest news, follow us on Twitter and LinkedIn or visit


Back to news